• HOME
  • IMMUNOTHERAPY
  • PATIENTS
  • INVESTORS
  • TEAM
  • CONTACT
  • German

SEARCH

   
Latest Info
  • LRT receives a positive ruling on the interim safety report
  • CELLMED assigns new CEO to push clinical program
  • © 2012 by CELL MED Research GmbH
  • Design by at2innovation
  • Powered by dRS4
  • Footer Navigation
    • IMPRINT
    • SEARCH
  • Login
    Login